Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26227296 | 1.00 | HDAC1 (0.51) | HDAC1GRIN2BNAMPTDEGS1BCL2 | |
| SCHEMBL20828520 | 0.87 | GRIN2B (0.47) | HDAC1GRIN2BNAMPTDEGS1BCL2 | |
| SCHEMBL5734042 | 0.86 | NNMT (0.58) | HDAC1GRIN2BNAMPTBCL2GSK3B | |
| SCHEMBL29651977 | 0.84 | HCAR3 (0.57) | HDAC1GRIN2BBCL2HCAR3 | |
| SCHEMBL31727242 | 0.84 | GRIN2B (0.48) | HDAC1GRIN2BNAMPTDEGS1BCL2 | |
| SCHEMBL28658285 | 0.84 | GRIN2B (0.48) | HDAC1GRIN2BNAMPTDEGS1BCL2 | |
| SCHEMBL2877186 | 0.84 | HCAR3 (0.57) | HDAC1GRIN2BBCL2HCAR3 | |
| SCHEMBL15059736 | 0.83 | GRIN2B (0.53) | HDAC1GRIN2BNAMPTDEGS1BCL2 | |
| SCHEMBL19580238 | 0.83 | PRMT1 (0.49) | HDAC1GRIN2BNAMPTDEGS1BCL2 | |
| SCHEMBL14652137 | 0.83 | GRIN2B (0.53) | HDAC1GRIN2BNAMPTDEGS1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC1 2/4885GRIN2B 987/4885NAMPT 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.